Insider · CIK 0001805916
Flagship Pioneering Fund VII, L.P.
Files at FHTX (Foghorn Therapeutics Inc.), GENB (Generate Biomedicines, Inc.). First filing -, latest -.
In brief
Flagship Pioneering Fund VII, L.P. files SEC Form 4 as director and 10% owner at FHTX (Foghorn Therapeutics Inc.), and also at GENB (Generate Biomedicines, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Flagship Pioneering Fund VII, L.P. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 16, 2025 | SYRS Syros Pharmaceuticals | 1,135,308 4.23% of outstanding | $272k | Dec 27, 2024 | $466k |
| Dec 27, 2024 | SYRS Syros Pharmaceuticals | 1,331,624 4.96% of outstanding | $280k | Dec 27, 2024 | $203k |
| Dec 13, 2024 | SYRS Syros Pharmaceuticals | 1,000,000 3.73% of outstanding | $230k | Dec 13, 2024 | none |
Transactions
Every row this insider has filed, 0 in all, newest first.
Questions about Flagship Pioneering Fund VII, L.P.
Answered from the filings on this page, as of the latest one.
Is Flagship Pioneering Fund VII, L.P. buying or selling?
Flagship Pioneering Fund VII, L.P. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Flagship Pioneering Fund VII, L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Flagship Pioneering Fund VII, L.P. has 0.
Where does Flagship Pioneering Fund VII, L.P. file Form 4?
Flagship Pioneering Fund VII, L.P. has filed Form 4 at FHTX (Foghorn Therapeutics Inc.); GENB (Generate Biomedicines, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.